Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06046482
Phase
PHASE2
Status
Terminated

Conditions

  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    Given by IV (vein)
  • Magrolimab — DRUG
    Given by IV (vein)
  • cetuximab — DRUG
    Given by IV (vein)
  • Docetaxel — DRUG
    Given by IV (vein)

Study Details

To learn if magrolimab, along with a combination of commercially-available drugs (cetuximab, pembrolizumab, and docetaxel) can help to control HNSCC in combination with other drugs. The safety of magrolimab will also be studied.

Key Dates

Start date
Nov 28, 2023
Status verified
Oct 2025
Primary completion
Aug 26, 2024
Completion
Aug 26, 2024

Study Design

Enrollment
4 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A
    Participants will receive magrolimab and cetuximab along with pembrolizumab.
  • Experimental: Cohort B
    Participants will receive magrolimab and cetuximab along with docetaxel.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: 140 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030-

Related coverage on Hipa.ai

Find similar trials in Houston, TX

By research site
M D Anderson Cancer Center· Houston, TX

Related Studies